Search

Zhang, L., X. Zhang, G. W. Barrisford, and A. F. Olumi. 2007. Lexatumumab (TRAIL-Receptor 2 MAb) Induces Expression of DR5 and Promotes Apoptosis in Primary and Metastatic Renal Cell Carcinoma in a Mouse Orthotopic Model.

Wang, Z., and A. F. Olumi. 2011. Diabetes, Growth Hormone-Insulin-Like Growth Factor Pathways and Association to Benign Prostatic Hyperplasia.

Aizer, A. A., J. J. Paly, A. L. Zietman, P. L. Nguyen, C. J. Beard, S. K. Rao, I. D. Kaplan, et al. 2012. Multidisciplinary Care and Pursuit of Active Surveillance in Low-Risk Prostate Cancer.

Aizer, A. A., J. J. Paly, A. L. Zietman, P. L. Nguyen, C. J. Beard, S. K. Rao, I. D. Kaplan, et al. 2013. Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer.

Yang, H., X. Chen, X. Wang, Y. Li, S. Chen, X. Qian, R. Wang, et al. 2014. Inhibition of PP2A Activity Confers a TRAIL-Sensitive Phenotype During Malignant Transformation.

Ge, R., Z. Wang, S. Wu, Y. Zhuo, A. G. Otsetov, C. Cai, W. Zhong, C. L. Wu, and A. F. Olumi. 2015. Metformin Represses Cancer Cells via Alternate Pathways in N-Cadherin Expressing Vs. N-Cadherin Deficient Cells.

Liu, D., J. E. Shoag, D. Poliak, R. S. Goueli, V. Ravikumar, D. Redmond, A. Vosoughi, et al. 2020. Integrative Multiplatform Molecular Profiling of Benign Prostatic Hyperplasia Identifies Distinct Subtypes.

Estevez, A., S. Kaul, A. Fleishman, R. Korets, P. Chang, A. Wagner, J. Bellmunt, A. F. Olumi, H. Rayala, and B. Gershman. 2023. Disparities in the Prevalence and Management of High-Risk Non-Muscle Invasive Bladder Cancer.

Ramos, F., R. Korets, A. Fleishman, S. Kaul, M. Johnson, J. L. Wei, A. F. Olumi, L. L. Tsai, and B. Gershman. 2023. Comparative Effectiveness of Magnetic Resonance Imaging-Ultrasound Fusion Versus In-Bore Magnetic Resonance Imaging-Targeted Prostate Biopsy.

Schaufler, C., S. Kaul, A. Fleishman, R. Korets, P. Chang, A. Wagner, S. Kim, et al. 2024. Immediate Radiotherapy versus Observation in Patients With Node-Positive Prostate Cancer After Radical Prostatectomy.